BrainStorm Cell Therapeutics Inc. expects to focus a new Phase III trial for NurOwn (debamestrocel) on amyotrophic lateral sclerosis patients with mild or less advanced disease, the company said in announcing withdrawal of the US biologics license application for the mesenchymal stromal cell therapy.
On 18 October, BrainStorm execs said they are withdrawing the NurOwn application, which was filed over protest by the Food...








